Selumetinib + Trastuzumab Deruxtecan for Pancreatic Cancer

This trial explores the safety and effectiveness of combining selumetinib and trastuzumab deruxtecan for treating advanced pancreatic cancer that cannot be surgically removed or has metastasized. Selumetinib blocks enzymes that promote cancer cell growth, while trastuzumab deruxtecan targets and delivers chemotherapy directly to specific cancer cells. Individuals diagnosed with HER2-positive pancreatic cancer, indicating the presence of a specific protein in their cancer cells, might be suitable for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this novel combination therapy.

Previous research has shown that the drugs selumetinib and trastuzumab deruxtecan have some safety in treating cancer. Studies found that patients taking selumetinib lived for a median of nine months. Another study showed that trastuzumab deruxtecan resulted in a median survival of 12.5 months, suggesting it might be more beneficial than other treatments.

While these studies didn't detail specific side effects, past trials revealed no major concerns, indicating these treatments are generally tolerable. However, since these are strong drugs meant to fight serious cancers, side effects are possible.

Selumetinib and Trastuzumab Deruxtecan are unique because they target pancreatic cancer in innovative ways. Unlike traditional treatments like chemotherapy, which broadly attacks rapidly dividing cells, Selumetinib specifically inhibits the MEK pathway, a critical route for cancer cell growth. Trastuzumab Deruxtecan, on the other hand, is an antibody-drug conjugate that delivers chemotherapy directly to cancer cells expressing the HER2 protein, minimizing damage to healthy cells. Researchers are excited about these treatments because they offer a more precise attack on cancer cells, potentially leading to better outcomes with fewer side effects.

Research has shown that trastuzumab deruxtecan (T-DXd) may help treat various cancers, including pancreatic cancer. In some studies, 37.1% of patients experienced tumor shrinkage or disappearance, known as the objective response rate (ORR). Many patients also maintained stable disease, meaning their cancer did not worsen for a period. This trial will administer a combination of selumetinib and T-DXd to participants. Selumetinib may inhibit tumor growth by blocking certain enzymes essential for cancer cell growth. This combination could benefit advanced pancreatic cancer. These findings suggest potential benefits, but further research is needed to confirm their effectiveness.⁶⁷⁸⁹¹⁰